Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

Horizon Pharma PLC announced that its Board of Directors has authorized a stock repurchase plan on Sunday, June 4th 2017, which allows the company to buyback 1,000% of outstanding shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.

Horizon Pharma PLC (NASDAQ:HZNP) announced its quarterly earnings results on Monday, May, 8th. The company reported $0.21 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.25 by $0.04. The company had revenue of $220.90 million for the quarter, compared to the consensus estimate of $248.71 million. Horizon Pharma PLC had a negative net margin of 21.26% and a positive return on equity of 21.51%. The company's revenue was up 7.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.34 EPS. View Horizon Pharma PLC's Earnings History.

12 brokerages have issued twelve-month price targets for Horizon Pharma PLC's shares. Their predictions range from $10.00 to $32.00. On average, they expect Horizon Pharma PLC's stock price to reach $20.42 in the next year. View Analyst Ratings for Horizon Pharma PLC.

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

• 1. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
• 2. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
• 3. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)
• 4. According to Zacks Investment Research, "Horizon’s growth-by-acquisition strategy, through which it actively pursues deals to expand and diversify its portfolio, is encouraging. The Raptor Pharma acquisition to strengthen its rare disease business is impressive. Moreover, the Hyperion and Crealta acquisitions bode well. However, the company’s efforts to expand Actimmune’s label suffered a developmental setback. Actimmune failed in a late-stage Friedreich's ataxia study, which could have given its sales a much-needed boost. Horizon is also involved in patent litigations with quite a few companies. Also, Horizon’s marketed products face intense competition. Pipeline setbacks, competitive pressures, concerns related to the ongoing litigations and focus on drug pricing remain material headwinds. The company has a negative record of earnings surprise in the last four trailing quarters while the estimates are stable ahead of Q4 results." (2/17/2017)
• 5. Jefferies Group LLC analysts commented, "Q2 results were well ahead of consensus (revs +10%, EPS +11%), driven by stronger revs from primary care products (+$19M vs JEF). This outperformance came despite higher than forecasted expenses (+$7M vs JEF). Mgt also reaffirmed its FY16 guidance – which appears increasingly achievable as improved GtN’s offset softening PCP Rxs." (8/4/2016)

Horizon Pharma PLC saw a increase in short interest in June. As of June 15th, there was short interest totalling 14,604,104 shares, an increase of 15.1% from the May 31st total of 12,691,454 shares. Based on an average daily trading volume, of 4,732,157 shares, the days-to-cover ratio is presently 3.1 days. Currently, 9.1% of the company's stock are short sold.

Some companies that are related to Horizon Pharma PLC include BTG plc (BTG), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Pacira Pharmaceuticals (PCRX), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Innoviva (INVA), Impax Laboratories (IPXL), Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Teligent (TLGT), Aceto Corporation (ACET), Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Tetraphase Pharmaceuticals (TTPH) and Corium International (CORI).

Horizon Pharma PLC's management team includes the folowing people:

• Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer
• Paul W. Hoelscher, Chief Financial Officer, Executive Vice President
• Brian K. Beeler, Executive Vice President, General Counsel
• David G. Kelly, Executive Vice President, Company Secretary and Managing Director, Ireland
• John B. Thomas, Executive Vice President, Strategy and Investor Relations
• Robert F. Carey, Executive Vice President, Chief Business Officer
• George P. Hampton, Executive Vice President - Orphan and Primary Care Business Units and International Operations
• Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer
• Timothy J. Ackerman, Senior Vice President - Commercial Operations
• Geoffrey M. Curtis, Senior Vice President - Corporate Communications

Horizon Pharma PLC's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.17%), Vanguard Group Inc. (7.85%), JPMorgan Chase & Co. (3.87%), Janus Capital Management LLC (2.71%), State Street Corp (2.69%) and Alliancebernstein L.P. (2.50%). Company insiders that own Horizon Pharma PLC stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma PLC.

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Teachers Advisors LLC, JPMorgan Chase & Co., Kennedy Capital Management Inc., Point72 Asset Management L.P., Stifel Financial Corp, Bank of Montreal Can and Systematic Financial Management LP. Company insiders that have sold Horizon Pharma PLC stock in the last year include Jeffrey W Sherman and Robert Carey. View Insider Buying and Selling for Horizon Pharma PLC.

Horizon Pharma PLC's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Highbridge Capital Management LLC, Janus Capital Management LLC, North Tide Capital LLC, Morgan Stanley, Capital Fund Management S.A., Alliancebernstein L.P. and Vanguard Group Inc.. View Insider Buying and Selling for Horizon Pharma PLC.

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Horizon Pharma PLC stock can currently be purchased for approximately $12.02.